Contribute Try STAT+ Today

The Federal Trade Commission is once again trying to block Illumina (ILMN), a dominant maker of genetic sequencing machines, from pursuing a big acquisition. And this time, the agency is targeting the planned $7.1 billion purchase of Grail, which is developing a long-sought blood test for detecting cancer early by using DNA sequencing.

Grail is one of several companies racing to develop these liquid biopsy tests, which analyze a sample of patient blood or other fluid through DNA sequencing. When the deal was announced last fall, Illumina pointed to two tests Grail is developing : one to detect cancer early in apparently healthy people, and another for potential cases of cancer in patients who have symptoms of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.